Sign in
CompletedPhase 4

Rescue Therapy for Helicobacter Pylori Infection

Key facts

Who runs it
Shanghai Jiao Tong University School of Medicine
Where
China3 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
360 people enrolled
Started
16 May 2023
Ended
31 Jan 2025
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Vonoprazan
  • Bismuth Potassium Citrate
  • Tetracycline
  • Metronidazole
  • Amoxicillin
  • Rifabutin
Record updated
15 September 2025

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Ability and willingness to participate in the study and to sign and give informed consent
  • Confirmed H. pylori infection and with previous treatment experience

Who cannot take part

  • Previous history of tuberculosis
  • administration of antibiotics, bismuth, antisecretory drugs, or Chinese herb medicine in the preceding 8 weeks
  • history of gastrectomy
  • Allergy to any of the study drugs
  • severe systemic diseases or malignancy
  • under 18 or over 80 years old
  • subjects naive to H. pylori treatment,
  • pregnant or lactating women

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Dual therapy containing vonoprazan and amoxicillin had showed excellent eradication results with Helicobacter pylori first-line treatment. However, no study has examined its efficacy for H. pylori rescue treatment. Rifabutin has low antibiotic resistance, superior antibacterial activity in vitro, and stability in the gastric acid environment. Several studies have confirmed the efficacy of rifabutin-containing triple therapy as a first-line or rescue treatment for H. pylori. The purpose of this study was to evaluate the efficacy and safety of dual therapy vesus rifabutin-containing triple therapy versus classical bismuth-containing quadruple therapy as rescue therapy for the eradication of refractory Helicobacter pylori.

The 3 groups in the trial

  • Tetracycline Bismuth Quadruple TherapyExisting treatment, for comparison

    Vonoprazan 20mg bid, Bismuth Potassium Citrate 110mg qid, Tetracycline 500mg qid, Metronidazole 400mg qid

    Treatment: Vonoprazan, Bismuth Potassium Citrate, Tetracycline, and Metronidazole

  • Rifabutin Triple TherapyTreatment being tested

    Vonoprazan 20mg bid, amoxicillin 1000mg tid, rifabutin 150mg bid

    Treatment: Vonoprazan, Amoxicillin, and Rifabutin

  • Dual TherapyTreatment being tested

    Vonoprazan 20mg bid, amoxicillin 1000mg tid

    Treatment: Vonoprazan and Amoxicillin

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Rifabutin-containing Triple Therapy for Helicobacter Pylori Rescue Treatment: a Randomized Controlled Trial
Publications
Record updated
15 September 2025